[go: up one dir, main page]

WO2001051067A1 - Composition anticoagulante a facteurs sanguins inactives multiples - Google Patents

Composition anticoagulante a facteurs sanguins inactives multiples Download PDF

Info

Publication number
WO2001051067A1
WO2001051067A1 PCT/US2000/034734 US0034734W WO0151067A1 WO 2001051067 A1 WO2001051067 A1 WO 2001051067A1 US 0034734 W US0034734 W US 0034734W WO 0151067 A1 WO0151067 A1 WO 0151067A1
Authority
WO
WIPO (PCT)
Prior art keywords
anticoagulant
composition
factors
anticoagulant composition
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/034734
Other languages
English (en)
Inventor
Richard J. Johnson
Roger Lundblad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Priority to AU2001257893A priority Critical patent/AU2001257893A1/en
Publication of WO2001051067A1 publication Critical patent/WO2001051067A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composition anticoagulante comprenant au moins deux facteurs sanguins inactivés dans un vecteur acceptable du point de vue pharmaceutique, les facteurs sanguins inactivés de ce type étant présents en un dosage efficace du point de vue pharmaceutique. Cette invention concerne également des procédés d'utilisation des compositions anticoagulantes de l'invention, comprenant l'administration à un patient d'une quantité desdites compositions permettant d'inhiber la coagulation, ainsi que des procédés de préparation de ces compositions.
PCT/US2000/034734 2000-01-13 2000-12-20 Composition anticoagulante a facteurs sanguins inactives multiples Ceased WO2001051067A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001257893A AU2001257893A1 (en) 2000-01-13 2000-12-20 Multiple inactivated blood factor anticoagulant composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17582100P 2000-01-13 2000-01-13
US60/175,821 2000-01-13
US74023900A 2000-12-18 2000-12-18
US09/740,239 2000-12-18

Publications (1)

Publication Number Publication Date
WO2001051067A1 true WO2001051067A1 (fr) 2001-07-19

Family

ID=26871605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034734 Ceased WO2001051067A1 (fr) 2000-01-13 2000-12-20 Composition anticoagulante a facteurs sanguins inactives multiples

Country Status (2)

Country Link
AU (1) AU2001257893A1 (fr)
WO (1) WO2001051067A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061428A3 (fr) * 2001-02-01 2003-04-17 Magnetic Biosolutions Sweden A Procede
WO2008145989A1 (fr) * 2007-05-30 2008-12-04 Nhs Blood And Transplant Procédé de préparation de facteur x, facteur x activé, facteur x inactivé et facteur xa désactivé, et compositions pharmaceutiques comportant de tels facteurs
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
CN112941143A (zh) * 2021-01-28 2021-06-11 南京可诺医疗技术有限公司 一种简单便捷的检测凝血和血小板功能的试剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5770699A (en) * 1994-10-28 1998-06-23 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5770699A (en) * 1994-10-28 1998-06-23 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KJALKE ET AL.: "Active site-inactivated factors VIIa, Xa and IXa inhibit individual steps in a cell-based model of tissue factor-intiated coagulation", THROMB HAEMOST., vol. 80, no. 4, October 1998 (1998-10-01), pages 578 - 584, XP002938760 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061428A3 (fr) * 2001-02-01 2003-04-17 Magnetic Biosolutions Sweden A Procede
US7279285B2 (en) 2001-02-01 2007-10-09 Magnetic Biosolutions Ab Method of reversibly disrupting a conjugate comprising a biotin compound and a biotin-binding compound
WO2008145989A1 (fr) * 2007-05-30 2008-12-04 Nhs Blood And Transplant Procédé de préparation de facteur x, facteur x activé, facteur x inactivé et facteur xa désactivé, et compositions pharmaceutiques comportant de tels facteurs
JP2010528096A (ja) * 2007-05-30 2010-08-19 エヌエイチエス ブラッド アンド トランスプラント 第Ｘ因子，活性化第Ｘ因子，不活性第Ｘ因子および不活性化第Ｘａ因子の調製方法、ならびに該因子を含む医薬組成物
US8906366B2 (en) 2007-05-30 2014-12-09 Nhs Blood And Transplant Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
CN112941143A (zh) * 2021-01-28 2021-06-11 南京可诺医疗技术有限公司 一种简单便捷的检测凝血和血小板功能的试剂及其应用

Also Published As

Publication number Publication date
AU2001257893A1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
US5066787A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
US5866122A (en) Pharmaceutical preparation for treating blood coagulation disorders
US5219995A (en) Plasma fraction purification
US4404132A (en) Blood coagulation promoting product
Stocker Defibrinogenation with thrombin-like snake venom enzymes
AU2006323849B2 (en) Method for preparing a factor H concentrate and the use thereof in the form of a drug
Kario et al. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis
JPH01193229A (ja) 抗血液凝固剤
WO1996013274A1 (fr) Procede de production de formes inhibees de facteurs sanguins actives
JPH03197495A (ja) 毒ヘビの毒ポリペプチド及び変異体
US5066788A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
WO2001051067A1 (fr) Composition anticoagulante a facteurs sanguins inactives multiples
US4361510A (en) Blood coagulation promoting product
EP0631501B1 (fr) Inhibition du facteur x provoquee par glycosylation
RS20050052A (sr) Farmaceutski aktivna supstanca preparata i lekova koji su u stanju da stvaraju trombin i/ili da sadrže trombin
Hirsh et al. C. Thrombogenesis
TWI441645B (zh) 作為新穎之局部用止血劑的活化型因子Ｘ（ＦＸａ）刺激劑
CA1170183A (fr) Produit favorisant la coagulation du sang
AU717123B2 (en) Glycosylation-mediated inhibition of factor X
Bussel Circulating anticoagulants: physiologic and pathophysiologic
Machin et al. Disorders of haemostasis
AU616159B2 (en) Method and therapeutic compositions for the treatment of bleeding disorders
Koller et al. Physiology and Pathology of Blood Coagulation A Review of the Literature of 1960 (Second Series)
ROBERT PRACTICAL USE OF ANTICOAGULANTS
Koller et al. Physiology and Pathology of Blood Coagulation A Review of the Literature of 1964 (Second Series)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP